Dr John W Stevens PhD, BSc (Hons)
Reader in Decision Science
University of Sheffield
Regent Court, 30 Regent Street
Sheffield, S1 4DA
Tel: (+44) (0)114 222 6396
Fax: (+44) (0)114 222 0749
My primary role is Director of the Centre for Bayesian Statistics in Health Economics (CHEBS). I graduated from Brunel University in 1982 with a BSc in Statistics/Mathematics. After graduating, I worked in the pharmaceutical industry for 24 years, including at SK&F Research Ltd (1982 – 1986), Wellcome Research Laboratories (1986 – 1995), GlaxoWellcome (1995 – 1996) and AstraZeneca R&D Charnwood (1996 – 2006). During this time I gained experience in the design and analysis of pre-clinical studies and in all phases of clinical drug development, and held a variety of management positions. In 1998, I assumed a technical role in the development and application of statistical methods to improve the drug development process, with a particular interest in Bayesian methods. During this time, I became interested in the application of Bayesian methods in health economics and was actively involved in the creation of CHEBS. My PhD was on latent variable modelling of effectiveness and resource use data in cost-effectiveness analyses of clinical trials. I moved to the University of Sheffield in November 2006 to provide leadership to CHEBS and further develop my Bayesian interests.
My research interests include:
- the application of Bayesian methods in drug development
- statistical methods in health economics
- evidence synthesis
- sample size determination under uncertainty
- adaptive dose finding
My teaching interests are:
- HAR670: Medical Statistics and Evidence Synthesis
- HAR6035: An Introduction to Medical Statistics and Critical Appraisal
- PAS6062: Further Clinical Trials
In addition to my role as Director of CHEBS, I am:
- a member of the National Institute for Health and Clinical Excellence (NICE) Appraisal Committee
- on the panel of expert reviewers for the National Institute for Health Research (NIHR) Health Technology Programme
- Editor-in-Chief of the Pharmaceutical Statistics journal
I am currently working on the following projects:
- An evidence synthesis, meta-analysis and decision analytic modelling following a systematic review of quantitative and qualitative studies evaluating the effectiveness, cost-effectiveness, safety and acceptability of interventions to prevent post-natal depression (PND). National Institute for Health Research: Health Technology Assessment Programme. 1 November 2012 – 31 January 2013. Co-investigator (£178,135)
- Bridging the age gap in breast cancer. Improving outcomes for older women. National Institute for Health Research. 1 June 2012 – 31 May 2017. Co-investigator (£590,105)
- Methods of extrapolating RCT evidence for economic evaluation. Medical Research Council: 1 October 2010 – 31 March 2012. Co-investigator (£313,888).
- Gray EP, Teare MD, Stevens J & Archer R (2016) Risk Prediction Models for Lung Cancer: A Systematic Review. Clinical Lung Cancer, 17(2), 95-106.
- Stevens JW, Khunti K, Harvey R, Johnson M, Preston L, Woods HB, Davies M & Goyder E (2015) Preventing the progression to Type 2 diabetes mellitus in adults at high risk: A systematic review and network meta-analysis of lifestyle, pharmacological and surgical interventions. Diabetes Research and Clinical Practice, 107(3), 320-331.
- Stevens JW, Simpson E, Harnan S, Squires H, Meng Y, Thomas S, Michaels J & Stansby G (2012) Systematic review of the efficacy of cilostazol, naftidrofuryl oxalate and pentoxifylline for the treatment of intermittent claudication.. Br J Surg, 99(12), 1630-1638.
- Turner RM, Lloyd-Jones M, Anumba DOC, Smith GCS, Spiegelhalter DJ, Squires H, Stevens JW, Sweeting MJ, Urbaniak SJ, Webster R & Thompson SG (2012) Routine antenatal anti-D prophylaxis in women who are Rh(D) negative: meta-analyses adjusted for differences in study design and quality.. PLoS One, 7(2), e30711. View this article in WRRO
- Stevens JW (2011) A note on dealing with missing standard errors in meta-analyses of continuous outcome measures in WinBUGS.. Pharm Stat, 10(4), 374-378.
- Nixon RM, O'Hagan A, Oakley J, Madan J, Stevens JW, Bansback N & Brennan A (2009) The Rheumatoid Arthritis Drug Development Model: a case study in Bayesian clinical trial simulation. PHARM STAT, 8(4), 371-389. View this article in WRRO
- O'Hagan A, Stevens JW & Campbell MJ (2005) Assurance in clinical trial design. PHARM STAT, 4(3), 187-201.
- O'Hagan A & Stevens JW (2003) Assessing and comparing costs: how robust are the bootstrap and methods based on asymptotic normality?. Health Econ, 12(1), 33-49.
- O'Hagan A & Stevens JW (2002) Bayesian methods for design and analysis of cost-effectiveness trials in the evaluation of health care technologies.. Stat Methods Med Res, 11(6), 469-490.
- Jackson C, Stevens J, Ren S, Latimer N, Bojke L, Manca A & Sharples L () Extrapolating Survival from Randomized Trials Using External Data: A Review of Methods. Medical Decision Making. View this article in WRRO